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26(4) 821-827. 1987.~The repeated intermittent administration of relatively low doses of amphetamine (AMPH) produces 
an enduring hypersensitivity to the motor stimulant effects of AMPH (behavioral sensitization), and this is accompanied by 
enhanced mesotelencephalic dopamine (DA) utilization/release. In contrast, chronic treatment with very high doses of 
AMPH does not produce sensitization, but is neurotoxic, resulting in the depletion of brain DA (and often other 
monoamines). However, gradually escalating doses of AMPH provide protection against the neurotoxic effects of higher 
doses given later. Therefore, the purpose of the present experiment was to determine if a regimen of gradually escalating 
doses of AMPH, culminating in much higher doses than usually used to study sensitization, would produce neural and 
behavioral changes associated with AMPH neurotoxicity (DA depletion) or behavioral sensitization (increased DA utiliza- 
tionl. Female rats were given 60 injections (2/day) of increasing (1 to 10 mg/kg) doses of d-AMPH, culminating in rats 
receiving 20 mg/kg/day for four consecutive days, This treatment did not deplete brain DA or serotonin, but did produce a 
long-lasting enhancement (at least 12 days) in striatal and nucleus accumbens DOPAC concentrations, and DOPAC/DA 
ratios. These neurochemical changes were accompanied by an enduring hypersensitivity to the stereotypy-producing 
effects of a subsequent AMPH "challenge.' In contrast to this enhanced response to a challenge, AMPH-pretreated rats 
showed a marked reduction in spontaneous nocturnal motor activity. It is concluded that rats can be given escalating doses 
of AMPH, which mimic to some extent the AMPH "runs' common in addicts and that this produces neural and behavioral 
changes consistent with the development of sensitization; not neurotoxicity. 
Amphetamine Sensitization Locomotion Motor activity Neurotoxicity Dopamine Striatum 
Nucleus accumbens Frontal cortex Serotonin Chronic treatment Amphetamine psychosis 
Dopamine metabolism 
IN humans chronic amphetamine (AMPH) use frequently man animals, and in the development of animal models 
produces an AMPH psychosis with clinical features that are AMPH psychosis. 
largely indistinguishable from paranoid schizophrenia [7,15]. One syndrome that has been proposed as an animal mod 
In addition, former AMPH addicts remain hypersensitive to of AMPH psychosis is called 'behavioral sensitizatio 
the psychotomimetic effects of AMPH even after years of ([17,42], for reviews see [32,41]). This refers to the progrt 
abstinence [37,41], suggesting that AMPH may produce sire and long-lasting hypersensitivity to the motor stimula 
persistent changes in neural regions that mediate the effects of AMPH produced by the repeated intermittent a 
psychotomimetic effects of AMPH. These clinical observa- ministration of AMPH. A second syndrome associated wi 
tions have prompted considerable interest in the long-term chronic AMPH treatment will be called 'AMP 
effects of stimulant drugs on brain and behavior in nonhu- neurotoxicity, '  and this refers to the progressive changes 
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brain and behavior produced by continuously maintaining 21 (8.0 mg/kg); 22-26 (9 mg/kg); and 27-30 (10 mg/kg). The~ 
elevated blood levels of AMPH for many days at a time fore, over the last 4 days of  the treatment schedule AMP 
[11,32]. This is usually achieved by implantation of  a sub- pretreated rats received two daily injections of  10 mg/kg. T 
cutaneous 'pellet '  that slowly releases AMPH [10], or by the animals were then used in either the neurochemical or beh~ 
frequent injection of  very high doses of  AMPH [23, 29, 43]. ioral study described below. 
The rationale for frequently administering high doses of 
AMPH to animals is that chronic AMPH users often take Neurochemical Study 
large quantities of  AMPH in ' runs '  that can last for 3-6 days Twelve days after the last injection of AMPH or salir 
[19], and researchers want to mimic this pattern of drug use during which time the animals were left undisturbed, ten 
[I1]. However,  as pointed out by Schmidtetal .  [39], chronic the AMPH-pretreated and six of the saline-pretreated n 
AMPH users build up to high doses gradually, as they de- were decapitated. After each brain was rapidly remov 
velop tolerance to AMPH's  autonomic effects. Therefore, (<30 sec) it was immediately put in ice-cold saline for 30- 
the abrupt administration of high doses of AMPH to nonhu- sec and then placed in a chilled cutting block. Brain slic 
man animals does no t  take into account changes in the ef- were obtained as described by Heffner et al. [12], but wi 
fects of AMPH that may be associated with gradually es- the following modifications. (1) Only the anteromedial pc 
calating doses [38,39]. tion of the frontal cortex anterior to the genu of  the corp 
Most s tud i e son theneuro log ica l consequenceso fch ron ic  callosum was removed (the dorsolateral cortex was d 
AMPH treatment have focused on mesotelencephalic carded). (2) The corpus of the stria(urn was removed witt 
dopamine (DA) systems, because AMPH causes DA release, 3.0 mm diameter micropunch. '(3) The nucleus accumbe 
and many of the behaviors evoked by AMPH are thought was removed with a 2.0 mm diameter micropunch. Tiss 
largely to be due to changes in DA activity. The repeated from the left and right hemispheres was pooled. 
intermittent administration of relatively low doses of AMPH As the dissection of each region was completed, the tiss 
(~<5.0 mg/kg), which produces behavioral sensitization, is pieces were weighed, placed in tubes containing 0.05 N pc 
associated with long-lasting increases in stimulated striatal chioric acid and dihydroxybenzylamine (DHBA; inten 
DA release in vitro [5, 18, 31, 34], and in nucleus accumbens standard), and then homogenized. Samples were centrifug 
and medial frontal cortex DA utilization [4, 24, 33]; but no at 5,000 × g for 45 rain at 2--4°C, the supernatant filter 
changes in DA concentrations [32]. In contrast,  the continu- through Arco LC3A 0.45/zm pore filters (Gelman Scienc~ 
ous infusion of  AMPH, or frequent injection of  multiple high Ann Arbor) and then stored frozen at -20°C for no mc 
doses, depletes striatal DA (and often serotonin), than 2 weeks before being assayed. Samples for a six po  
presumably due to terminal degeneration [10, 23, 28, 29.43]. standard curve were prepared in the perchloric acid/DHt 
Furthermore,  there appears to be a reduction in the ability of solution at the same time. Tissue concentrations of dot 
a challenge injection of  AMPH to enhance dopaminergic ac- mine (DA), dihydroxyphenylacet ic  acid (DOPAC), 
tivity in animals pretreated with toxic doses of AMPH [38]. hydroxytryptamine (5-HT) and 5-hydroxyindoleacetic a~ 
However,  it appears that prior exposure to gradually increas- (5-HIAA) were subsequently determined by high perfor: 
ing doses of AMPH provides considerable protection against ance liquid chromatography with electrochemical detectic 
the neurotoxic effects of high doses given later [39]. There- 
fore, the purpose of  the present experiment was to determine using procedures similar to those described previously [3 
if a regimen of gradually escalating doses of d -AMPH,  cul- 
Behavioral Studies minating in much higher doses than usually used to study 
sensitization, would produce neural and behavioral changes The remaining animals (7 saline- and 7 AMPH-pretreate 
usually associated with AMPH neurotoxicity or behavioral were left undisturbed in their home cages for 2 days folio 
sensitization. In addition, spontaneous nocturnal motor ac- ing the last pretreatment injection, and were then transferr 
tivity was studied following the cessation of AMPH treat- to wire-hanging cages adapted for measuring motor activil 
ment to determine if normal activity rhythms were changed These cages were similar to the home cages, but twice 
by prior exposure to AMPH. long ( 'double '  cages: 41×24× 18 cm), and were equipp 
with two pairs of infrared photocells situated along the 1o 
METHOD axis of the cage. The photocell pairs were mounted 5.0 
above the cage floor and 25.2 cm apart from each other: th 
Thirty adult (200-300 g) female Sprague-Dawley derived dividing the cage into a central area (25.2 cm long) in whi 
rats (Holtzman Co., Madison. WI) were housed individually there was no photocell beam, and two 7.9 cm long areas 
in wire-hanging cages in a temperature-controlled room, on a the extreme left and right ends of the cage, in which t 
normal light:dark cycle (14:10 hr, with the lights going on at presence of a rat would result in disruption of a photoc 
08:00 hr). Food and water were freely available, beam. Disruption of a photocell beam was detected by 
Each rat received two daily intraperitoneal injections of microcomputer,  which registered the total number of be~ 
either 0.9% saline (1 ml/kg; n= 13) or d-amphetamine sulfate "breaks" over any specified interval. Disrupting one be~ 
(AMPH), with 8-10 hr separating the two daily injections, registered a single count, but another count could not 
Immediately following the injection each rat was returned to registered by that beam until the second photocell beam 
its home cage. Injections were given on each consecutive the other end of the cage was disrupted. Therefore, act iv 
weekday for 6 weeks, but not on weekends (i.e., there were counts in this apparatus reflect locomotion from one end 
two drug-free days after each 10 consecutive injections), the cage to the other, and not the repetitive disruption o f o  
AMPH:pret rea ted  rats (n= 17) received increasing doses of beam. 
AMPH for a total of 60 injections over  42 days (30 injection The animals remained in these activity monitors for 
days), according to the following schedule: Injection days hr/day for the next i0 days. The animals were left 
1-2 (1.0 mg/kg); 3-5 (2.0 mg/kg); 6 (3.0 mg/kg); 7-11 (4.0 habituate for the first 5 days.  but for the next 5 days activ 
mg/kg); 12-15 (5.0 mg/kg); 16 (6.0 mg/kg): 17-20 (7.0 mg/kg): was monitored over 30 rain intervals for 20 hr/day. The lig 
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TABLE 1 
MEAN (±S.E.M.) TIssUE CONCENTRATIONS (ng/mg) OF DOPAMINE, DIHYDROXYPHENYLACET1C ACID (DOPAC). 
5-HYDROXYTRYPTAMINE (5-HT), 5-HYDROXYINDOLEACETIC ACID (5-HL&AL AND THE MEAN DOPAC/DA AND 5-H1AA/5-HT RATIOS II ~ 
SALINE AND AMPHETAMINE (AMP)-PRETREATED RATS 
Dopamine DOPAC DOPAC/DA 5-HT 5-HIAA 5-HIAA/5-H'] 
Striatum 
Saline (5) 21.37 ± 0.81 2.23 ± 0.18 0.104 ___ 0.01 0.824 ± 0.10 0.959 ± 0.08 1.19 -~ 0.06 
AMP (10) 21.47 ± 0.81 3.03 ± 0.21" 0.140 ± 0.01, 0.746 ± 0.09 0.923 ± 0.06 1.36 ± 0.15 
Nucleus Accumbens 
Saline (6) 14,03 ± 0.12 2.92 ± 0.32 0.206 ± 0.01 0.828 ± 0.13 0.910 ± 0.09 1.19 ± 0.17 
AMP {10) 15.77 ± 0.08 3.72 ± 0.21" 0.236 ± 0.01" 0.983 ± 0.13 1.028 ± 0.11 1.09 ~- 0,10 
Medial Frontal Cortex 
Saline (6} 0.178 ± 0.02 0.168 ± 0.03 1.00 ± 0.19 1.120 ± 0.05 0.643 ± 0.05 0.58 ± 0.05 
AMP (10) 0.228 ± 0.01 0.176 _ 0.02 0.82 ± 0.14 0.979 ± 0.09 0.650 ___ 0.03 0.75 _+ 0.10 
*Differs from the saline control group, p<0.05: tp<0.01. Number in parentheses=number of animals. 
dark cycle was the same as in the home colony room. 
Twelve days after the last pretreatment with saline or AMPH 25 I- 
all animals received a challenge injection (IP) of 2.0 mg/kg 03 
d-amphetamine sulfate, and AMPH-induced stereotyped be- Z 2 0  
havior and locomotion (photocell disruptions over 5 min D 
intervals) were quantified over the next ~ hr. 0 SALINE-~ 
" (~ 15- * 
Stereotyped behavior was rated by an observer  (D.M.C.), L.~ r -  ~ t ~  ~ 
who was unaware of the pretreatment conditions, every 10 ,>- 
min following the injection of AMPH. Overall s tereotypy I 0  , 
was assessed by use of  the 9-point scale described by Ellin- 
wood and Balster [9], in which a score of l=as leep ,  .~  
2=inactive,  3=normal  in place activity, 4=normal ,  alert, 
active, 5 = hyperactive,  6= slow patterned stereotypy,  7=fast  ¢:~ 
I 
patterned stereotypy,  8=restr icted (focussed) stereotypy, 17:00 22;00 3 :00  8:00 
and 9=dyskinet ic  (see Ellinwood and Balster [9] for a more 
complete description of the rating scale). In addition, sub- I I I I I 
components of  s tereotyped activity, including repetitive Lig'hB On Lights Off 
sniffing behavior,  repetitive movements of the head and TIME (hours) 
limbs and repetitive oral behaviors (licking and biting) were 
rated according to their intensity ( l=mi ld ,  2=moderate ,  FIG. 1. Mean spontaneous activity counts averaged over 30 tr 
3 =intense) and duration (1 =discontinuous,  2=continuous),  intervals for 20 consecutive hours (16:00 to 12:00 hr) in amphetami 
IAMPH)- and saline-pretreated rats (n=7/group). In this apparal 
as described by Rebec and Segal [26]. For  each subcompo- activity counts reflect locomotion from one end of the cage to t 
nent of stereotypy the intensity and duration scores were other (see the Method section). AMPH-pretreated rats were signi 
multiplied together to yield a single rating at each time inter- cantly less active than saline controls, as indicated by a two-w 
val. ANOVA with repeated measures over all 20 intervals (Main Effc 
F---28.3, p<0.001; Interaction F=4.5, p<0.001). Analyses comp~ 
RESULTS ing the two groups just during the dark part of the light:dark cy~ 
(lights off), or just during the 6 hr prior to lights off were also statis 
Neurochemistry cally significant (ANOVAs, p<0.05). Asterisks indicate individl 
Table 1 presents the mean concentrations of  DA, comparisons significant at thep<0.01 level (t-tests). 
DOPAC. 5-HT and 5-HIAA in the striatum, nucleus accum- 
bens and medial frontal cortex of AMPH-pretreated and con- increased DOPAC/DA ratios in the striatum, t (13)=3 
trol animals. The striatal sample from one control animal was p=0.003,  and nucleus accumbens,  t(14)=2.4, p =0.03, I~ 
lost, and that is why there are only 5 animals in that group, not medial frontal cortex (Table 1). 
The DOPAC/DA and 5-HIAA/5-HT ratios, which provide an 
index of DA and 5-HT utilization, respectively [27, 36, 44], Behavior 
are also shown. 
AMPH-pretreatment  had no affect on DA, 5-HT or Spontaneous activity. Figure 1 illustrates the averag, 
5-HIAA concentrations,  or 5-HIAA/5-HT ratios, in any of spontaneous activity of saline and AMPH-pretreated r, 
the structures sampled (2-tailed t-tests). However ,  AMPH- over a 20 hr period. Data from the remaining 4 hr/day we 
pretreatment did produce a significant increase in DOPAC not included to minimize disturbances associated with fee 
concentrations in the striatum, t(13)=2.5, p=0.026,  and nu- ing, watering, cage-cleaning and data collection (printi~ 
cleus accumbens,  t(14)=2.2, p=0.043,  but not in the medial that occurred during this period. The data shown in Fig. 
frontal cortex. Similarly, AMPH-pretreatment  significantly were averaged over the 5 consecutive days of testing to 1 
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OVERALL STEREOTYPY markedly less active than saline-pretreated controls, and tt 
p <.O03 was especially evident during the period immediately follo' 
ing lights off, and just prior to lights on (Fig. 1). During tJ 
7 ~ ' / ~ H  middle of the dark period (around interval 20)both grou 
showed similar relatively low levels of activity, but were st 
more active than during the day. 
AMPH-induced behavior. As described previously (e.! 
~ ~  [42]), a 2.0 mg/kg challenge injection of  AMPH produced 
typical triphasic pattern of behavioral change consisting c 
(1) an initial enhancement in locomotor activity; (2) follow~ 
by a period of stereotyped behavior during which locomot 
2 4 6 8 I0 12 activity was much diminished; and (3) a post-stereotYl 
period of  heightened locomotion. However, the response 
ILl SNIFFING AMPH-pretreated rats was significantly different from th 
of saline-pretreated controls, and the difference was typic 
rr  Z / ~ r  p<,O0 2 of that associated with sensitization to AMPH. Figure 2 illu O ' ' 
5 trates the stereotypy ratings obtained over 2 hr following t] 
~. 4 AMPH challenge, and it is obvious that AMPH-pretreat~ 
a. rats showed a more rapid onset of stereotyped behavior at 
>" 3 more intense stereotyped behavior than did saline-pretreat~ 
S controls. This dose of AMPH did not produce oral stere 
u.I 2 typies in any of the saline-pretreated rats, but 3/7 of tl 
r~ AMPH-pretreated rats did show periods of licking and gna~ 
J - ing. Although the data are not shown, analysis of activi 
[ " -  l ~ I I I i 
03 2 4 6 8 I0 12 counts (photocell beam disruptions) resulted in the chara 
teristic differences between AMPH- and saline-pretreat~ 
animals (F=2.5, p<0.00l)  described extensively by Seg 
HEAD ~ LIMB MOVEMENTS and colleagues [41,42], i.e.. a more rapid onset of stereotyt 
4 (cessation of locomotion) in AMPH-pretreated animals. 
Lastly, the AMPH treatment regimen did not significant 
5 disrupt growth rate in these animals, and if anything the 
was a tendency for AMPH-pretreated rats to gain mo 
2 I/~/, ~ ~ ~ , ~ ~ Q . 3  weight than saline controls. On the first treatment day tl 
saline group weighed an average (--+SEM) of 193---4.5 g az 
the AMPH group 194~-2.4 g; on the last treatment day th~ 
I weighed 267___ 10.1 and 276=6.4 g, respectively; and on tl 
challenge day 275___ 10.8 and 295-_. 1.9 g, respectively. 
2 4 6 8 I0 12 DISCUSS/ON 
TEN MINUTE INTERVALS 
In the present study female rats received 60 injections, 
FIG. 2. Mean (_-S.E.M.) stereotypy rating scores for AMPH-and increasing doses of AMPH, culminating with rats receivit 
saline-pretreated rats (n=7/group). Twelve days after the last treat- 20 mg/kg/day for 4 consecutive days. This treatment regim~ 
ment with saline or AMPH each rat received a challenge injection of was designed to mimic, to some extent, the pattern of drt 
2.0 mg/kg d-AMPH, and then were rated once every 10 rain for the use seen in AMPH addicts [19]. In this regard it is wor  
next 2 hr. Mann-Whitney U-tests were conducted on the cumulative 
rating scores, and AMPH-pretreated rats showed significantly noting that a 65 kg human taking 20 mg/kg/day would use 1 
greater overall stereotypy (top; U=4. p<0.003), repetitive sniffing grams/day. The purpose of this study was to determine ifth 
(middle; U=3, p<0.002), and repetitive head and limb movements regimen of gradually escalating doses of AMPH wou 
(bottom: U=I.5, p<0.001)than did saline-pretreated controls, produce neurochemical and behavioral changes normal 
associated with the phenomenon of behavioral sensitizatio] 
or with the phenomenon of AMPH neurotoxicity ([32] fi 
review). Both the neurochemical and behavioral changes oi 
duce intra-subject variability associated with the estrous cy- served are clearly consistent with the induction of sensitiz; 
cle. Each rat would have had one and only one complete tion. and not with AMPH neurotoxicity. 
estrous cycle during this time. Exactly the same pattern of 
results was present when data for each day were analyzed 
separately. Nettrochemical Chan k, es 
Both groups showed the same pattern of  activity over the It is well established that the continuous infusion or r 
light:dark cycle: i.e., relatively low levels of activity during peated administration of  very high doses of AMPH is toxic 1 
the day; a large increase immediately following lights off; a monoaminergic neurons, and that this is typically manife 
reduction in activity during the middle of  the dark period; a by a persistent depletion of forebrain DA and/or 5-H" 
second rise in activity towards the end of the dark period; presumably due to terminal degeneration [10, 23, 25, 28, 2 
and then a marked decline with lights on (Fig. 1). During the 38, 39, 43]. Doses comparable to those used here have bee 
light period there were only small differences in activity be- reported to be sufficient to produce a long-lasting depletic 
tween the 2 groups, but there were large group differences in of striatal DA, for example, twice daily SC injections of 12 
nocturnal activity. At night AMPH-pretreated rats were mg/kg d-AMPH for 4 days [40]. However, the present trea 
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ment regimen was not toxic to monoaminergic neurons, as frontal cortex DA metabolism in the present study. This d 
indicated by normal tissue concentrations of DA and 5-HT in serves mention because we previously reported that sensi 
the striatum, nucleus accumbens and medial frontal cortex, zation to AMPH is accompanied by an increase in medi 
There are probably a number of reasons for this. (1) frontal cortex DA utilization [33]. When we have estimatq 
Monoamine neurons are particularly sensitive to damage the 'resting" rate ~ffDA utilization by measuring the decli~ 
when elevated blood levels of AMPH are continuously main- in DA after an injection of alpha-methyl-p-tyrosine we ha' 
tained, and less sensitive to intermittent injections, as used consistently (two independent experiments) found that se 
here [32]. (2) In the present study animals were given gradu- sitized rats show enhanced DA utilization in the medial fro 
ally escalating doses of AMPH,  and it has been shown this tal cortex, but not in the striatum [33]. In contrast,  when 
provides considerable protection against the toxic effects of have measured 'resting" DA metabolite concentrations m 
subsequent high doses [39]. (3) In many studies describing metabolite/transmitter ratios we have consistently found th 
AMPH neurotoxicity,  especially in which 5-HT systems sensitized female rats show enhanced DA metabolism in t] 
were damaged, meth-AMPH was used. In rats meth-AMPH striatum, but not medial frontal cortex ([4]; and the prese 
is probably more toxic than d-AMPH [25.32]. Nevertheless,  study}, it is not known what accounts for this discrepancy. 
the present study clearly shows that rats can be given re- may be related to the large regional differences in the ba,. 
peated high doses o fd -AMPH without producing neurotoxic rate of DA utilization [2], and/or regional differences in t] 
effects, sensitivity to stress (e.g.. [35.45] and below). 
Although this AMPFI treatment regimen did not deplete 
forebrain DA, it did enhance striatal and nucleus accumbens Behavior 
DA metabolism, as indicated by elevated DOPAC concen- 
trations. The increase in DOPAC concentrations, and The behavioral response to a challenge injection 
DOPAC/DA ratios, suggests that AMPH pretreatment AMPH observed here was typical of that frequently d 
produced a long-lasting fat least 12 days) increase in striatal scribed in animals sensitized to AMPH [32]. AMP] 
and nucleus accumbens DA utilization. The ratio of pretreated rats showed a more rapid onset of stereotyp. 
DOPAC/DA does not always provide a good index of DA .behavior, and more intense stereotyped movements than d 
utilization, because after the administration of many psycho- %aline controls. These behavioral observations further su 
active drugs DA metabolism can be dissociated from DA port the contention that the gradually escalating doses 
utilization/release [6,47]. However,  in nondrugged animals, AMPH used here produced sensitization. 
such as those studied here, there is considerable evidence The marked nocturnal hypoactivity shown by AMP] 
that DOPAC/DA ratios provide a reasonably good index of pretreated animals was unexpected. To our knowledge, tt 
DA utilization [21, 27, 36]. is the first report of abnormalities in the spontaneous beha 
The suggestion that this AMPH treatment regimen en- ior of AMPH-sensit ized animals, which persists for mo 
hanced DA utilization is consistent with some studies on the than a week after the cessation of drug treatment. Typicall 
neurochemical correlates of behavioral sensitization. For  behavioral abnormalities in AMPH-sensit ized animals ha 
example, it has been reported that sensitization is accom- been observed only following a challenge, either with AMF 
panied by an enduring enhancement in AMPH [18, 31, 34], or stress [32]. The decrease in nocturnal activity shown 1 
potassium and electrical stimulation-induced striatal DA re- AMPH-pretreated rats is especially striking when contrast  
lease [5], and in striatal DA metabolism [4.46]. However.  with the exaggerated behavioral response produced by 
there have been numerous reports that sensitization does not AMPH challenge. It is not known how long this nocturr 
alter steady-state (resting) levels of DA metabolism [14.20, hypoactivity persists,  or whether it is produced by less e 
22, 24] but only the response to a subsequent challenge [32]. treme AMPH treatment regimens. However,  if the neul 
Of course, differences between these latter studies and the changes responsible for the decrease in spontaneous activi 
present one could be due to the relatively extreme AMPH are related to those responsible for behavioral sensitizatic 
treatment regimen used here. However,  another possibility the effect may persist for very long periods of time. 
is that female rats were used in the present study, and in Although the hypoactivity seen in AMPH-pretreat  
most previous studies with negative results male rats were animals was by far most pronounced during the dark part 
used. Consistent with this idea, we have found that the be- the light:dark cycle, there was also a tendency for them to ! 
havioral sensitization produced by a much less extreme relatively inactive during the lights-on period as well. T~ 
AMPH treatment regimen than used here is accompanied by effect was very small but statistically significant when all t 
enhanced striatal DA metabolism in female, but not male rats observation periods before lights off (i.e., the first 6 hr 
[4]. This sex difference in the persistent neurochemical ef- Fig. I). were included in an analysis of variance (grol 
fects of  repeated AMPH treatment may be related to sex F=7.0 ,  p<0.03).  At the very least, AMPH-pretreat,  
differences in the development of behavioral sensitization, animals were not more active than controls during the d~ 
Females show much more robust behavioral sensitization This observation prompts speculation regarding the signi 
than males [4, 30, 34]. This is not to say that AMPH treat- cance of the enhancement in resting DA metabolism found 
ment produces qualitatively different effects in males and the striatum and nucleus accumbens of AMPH sensitiz 
females, because both sensitized males and females are rats. 
hyperresponsive to an AMPH challenge [5, 18, 31, 34]. Fur- Present knowledge concerning the role of mesostr ia  
thermore, a subgroup of male rats showing the most robust and mesolimbic DA neurons in controlling motor activi 
behavioral sensitization do have increased striatal DA me- suggests that an enhancement in dopaminergic activi 
tabolism (unpublished observations). Therefore, it is most should be accompanied by an increase in motor activity, 
likely that the sex difference is quantitative, and that rela- the hypoactivity reported here [ 13]. Of course, this appare 
tively small changes during the resting state are more consis- paradox may simply reflect a lack of correlation between t 
tently apparent in highly sensitized females [32]. measures of DA metabolism used here, and DA utilizati, 
There was no effect of AMPH pretreatment on medial [6,47]. However,  if the enhancement in DOPAC concenu 
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tions and DOPAC/DA ratios in fact do reflect increased DA desire for more. Of course, reexposure to AMPH would le 
utilization, why is this accompanied by apparent hypoactiv- to an exaggerated dopaminergic response (sensitizatio 
ity? The answer to this question is unknown, but one perhaps related to the paranoid psychotic reaction that 
possibility is that the neurochemical measures reported here frequently develops with repeated stimulant drug use [7, 
do not in fact reflect the resting state, but a rapid response to 41]. 
stress. In summary, the present study shows that rats can 
In the present study 2-3 min could pass after a rat was given a regimen of escalating doses o fd-AMPH,  culminati 
removed from its home cage before it was decapitated. This in the repeated administration of very high doses, withe 
amount of  time may be enough for the emergence of stress- producing neurotoxic effects. Animals given this treatme 
related changes in DA metabolism (utilization?). This idea is regimen showed enduring behavioral and neurochemi~ 
consistent with reports that intense environmental stimuli changes associated with the development of sensitizatk 
(stressors) can produce very rapid (a few rain) increases in including enhanced stereotyped behavior following 
dopaminergic activity [8, 16, 21, 35]. Furthermore, AMPH- AMPH challenge, and enhanced striatal and nucleus accu 
pretreated rats are hypersensitive to stress, as indicated by bens DA metabolism [32]. Finally, AMPH-pretreat 
behavioral [1] and neurochemical studies [35]. Therefore, animals also showed a marked reduction in spontaneous nc 
sensitized animals may show an even'more rapid and intense turnal motor activity (locomotion), which persisted for 
response to removal from the home cage, and the associated least 12 days following the last exposure to AMPH. It 
handling, than normally expected. If this is the case, the suggested that the persistent behavioral and neurochemi~ 
enhanced striatal and nucleus accumbens DA metabolism changes produced by repeated AMPH treatment found he 
reported here could reflect the response to a 'stress chal- may be related to some of the persistent behavioral and cc 
lenge,'  consistent with the behavioral hypersensitivity to the nitive effects of AMPH reported in people who chronica 
AMPH challenge, rather than reflecting the resting state. Of abuse stimulant drugs. 
course, it follows from this argument that if sensitized 
animals are left undisturbed, some DA systems may actually 
be hypoactive, which would coincide with a reduction in ACKNOWLEDGEMENTS 
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